Description
The CDH17 antibody (Cadherin 17 or LI-cadherin) is a newly identified oncogene implicated in tumor invasion and metastasis, and it is expressed in the intestinal epithelium. CDH17 is an exceptionally specific marker for colon cancer (99/99, 100%) and has greater sensitivity compared to CDX2 (93/99, 94%) and CK20 (91/99, 92%). The overexpression of CDH17, along with the underexpression of CDX2, is associated with a poor prognosis in patients with epithelial ovarian cancer. CDH17 may facilitate the early diagnosis of Barrett’s esophagus. CDH17 has proven to be an effective marker for differentiating primary urinary bladder adenocarcinoma from urothelial carcinoma exhibiting glandular differentiation. It is important to note that it does not differentiate primary urinary bladder adenocarcinoma from colorectal cancer that secondarily involves the bladder.
Specifications
| Weight | .4 lbs |
|---|---|
| Dimensions | 1 × 1 × 1 in |
| Intended Use | RUO |
| Source | Mouse Monoclonal |
| Clone | 1H3 |
| Isotype | IgG1/kappa |
| Antigen | CDH17 |
| Localization | Cytoplasmic and cell membrane |
| Positive Control | Colon Carcinoma |
